NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage biotechnology company developing broad-spectrum antiviral therapies based on its proprietary host-mimetic nanomedicine platform, announced the pricing of a $3.8 million registered direct offering with a single fundamental institutional investor. The financing consists of 2,516,339 shares of common stock (or pre-funded warrants in lieu thereof), together with accompanying warrants to purchase up to 2,516,339 additional shares at an exercise price of $1.75 per share, expiring five and one-half years from issuance.
Net proceeds are expected to support the continued advancement of the Company’s antiviral drug development programs and general corporate purposes. D. Boral Capital LLC acted as the exclusive placement agent.
Lucosky Brookman LLP served as counsel to NanoViricides, Inc. in connection with the offering
